AU2010310786B2 - AKT inhibitors - Google Patents

AKT inhibitors Download PDF

Info

Publication number
AU2010310786B2
AU2010310786B2 AU2010310786A AU2010310786A AU2010310786B2 AU 2010310786 B2 AU2010310786 B2 AU 2010310786B2 AU 2010310786 A AU2010310786 A AU 2010310786A AU 2010310786 A AU2010310786 A AU 2010310786A AU 2010310786 B2 AU2010310786 B2 AU 2010310786B2
Authority
AU
Australia
Prior art keywords
imidazol
ethyl
tert
butyl
piperidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010310786A
Other languages
English (en)
Other versions
AU2010310786A1 (en
Inventor
Douglas Wade Beight
Timothy Paul Burkholder
Joshua Ryan Clayton
Marijean Eggen
Kenneth James Junior Henry
Deidre Michelle Johns
Saravanan Parthasarathy
Huaxing Pei
Mark Edward Rempala
Jason Scott Sawyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2010310786A1 publication Critical patent/AU2010310786A1/en
Application granted granted Critical
Publication of AU2010310786B2 publication Critical patent/AU2010310786B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2010310786A 2009-10-23 2010-10-20 AKT inhibitors Ceased AU2010310786B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25430809P 2009-10-23 2009-10-23
US61/254,308 2009-10-23
PCT/US2010/053295 WO2011050016A1 (en) 2009-10-23 2010-10-20 Akt inhibitors

Publications (2)

Publication Number Publication Date
AU2010310786A1 AU2010310786A1 (en) 2012-04-19
AU2010310786B2 true AU2010310786B2 (en) 2014-03-27

Family

ID=43467018

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010310786A Ceased AU2010310786B2 (en) 2009-10-23 2010-10-20 AKT inhibitors

Country Status (12)

Country Link
US (1) US8436002B2 (enExample)
EP (1) EP2491032B1 (enExample)
JP (1) JP5581390B2 (enExample)
KR (1) KR101398268B1 (enExample)
CN (1) CN102574852B (enExample)
AU (1) AU2010310786B2 (enExample)
BR (1) BR112012011328A2 (enExample)
CA (1) CA2778291C (enExample)
EA (1) EA020151B1 (enExample)
ES (1) ES2465094T3 (enExample)
MX (1) MX2012004780A (enExample)
WO (1) WO2011050016A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102123131B1 (ko) 2012-05-17 2020-06-15 제넨테크, 인크. 하이드록실화 사이클로펜타피리미딘 화합물 및 이의 염의 제조 방법
JP6214636B2 (ja) 2012-05-17 2017-10-18 アレイ バイオファーマ、インコーポレイテッド ヒドロキシル化シクロペンチルピリミジン化合物を作製するためのプロセス
DK2861582T3 (en) 2012-05-17 2016-08-22 Array Biopharma Inc A process for preparing hydroxylated compounds cyclopentylpyrimidin
DK2858989T3 (da) 2012-05-17 2020-06-02 Genentech Inc Amorf form af en AKT-hæmmende pyrimidinyl-cyclopentan-forbindelse, sammensætninger deraf og fremgangsmåder dertil
CN104520263B (zh) 2012-05-17 2016-11-09 基因泰克公司 制备氨基酸化合物的方法
ES2807539T3 (es) * 2012-11-16 2021-02-23 Merck Patent Gmbh Derivados de imidazol-piperidinilo como moduladores de la actividad de quinasa
SG11201505999VA (en) * 2013-03-11 2015-08-28 Merck Patent Gmbh 6-[4-(1 h-imidazol-2-yl)piperidin-1 -yl]pyrimidin-4-amine derivatives as modulators of kinase activity
CA2928568A1 (en) 2013-07-26 2015-01-29 Update Pharma Inc. Combinatorial methods to improve the therapeutic benefit of bisantrene
CA3206628A1 (en) 2013-09-12 2015-03-19 Dana-Farber Cancer Institute, Inc. Methods for evaluating and treating waldenstrom's macroglobulinemia
GB201401198D0 (en) * 2014-01-24 2014-03-12 Bial Portela & Ca Sa Process for the syntheis of substituted urea compounds
US9925192B2 (en) 2014-02-28 2018-03-27 Merck Sharp & Dohme Corp. Method for treating cancer
RU2713181C1 (ru) * 2016-05-20 2020-02-04 Тайхо Фармасьютикал Ко., Лтд. Новое производное 5h-пирроло[2,3-d]пиримидин-6(7h)-она
PL3919491T3 (pl) * 2019-01-29 2025-10-20 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. Inhibitor akt
PH12022553031A1 (en) * 2020-05-08 2024-05-13 Georgiamune Inc Akt3 modulators
WO2021228223A1 (zh) * 2020-05-15 2021-11-18 南京正大天晴制药有限公司 氘代akt激酶抑制剂
US20230271958A1 (en) * 2020-07-22 2023-08-31 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. SALT AND CRYSTAL FORM OF DIHYDROPYRIDO[2,3-d]PYRIMIDINE DERIVATE
AU2021314419B2 (en) * 2020-07-22 2023-12-07 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. Salt of dihydropyrido[2,3-d]pyrimidinone derivative, preparation method therefor, and use thereof
CA3186565A1 (en) * 2020-07-22 2022-01-27 Lei Miao Unit dosage composition of akt inhibitor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008075109A1 (en) * 2006-12-21 2008-06-26 Astex Therapeutics Limited Substituted piperidines having protein kinase inhibiting activity

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
NL1004346C2 (nl) 1996-10-23 1998-04-24 Dsm Nv Werkwijze voor het scheiden van een mengsel van enantiomeren in een geschikt oplosmiddel.
BR0307544A (pt) 2002-02-01 2004-12-07 Ariad Gene Therapeutics Inc Compostos contendo fósforos, componentes e composição bem como, sua utilização através de métodos de tratamentos
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
WO2005117909A2 (en) 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
RU2346996C2 (ru) 2004-06-29 2009-02-20 ЮРОПИЭН НИКЕЛЬ ПиЭлСи Усовершенствованное выщелачивание основных металлов
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
EP1828186A1 (en) * 2004-12-13 2007-09-05 Sunesis Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors
US7994172B2 (en) * 2004-12-28 2011-08-09 Exelixis, Inc. [1H-pyrazolo[3, 4-D]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (P70s6k, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases
EP1895898B1 (en) 2005-06-29 2011-02-16 Compumedics Limited Sensor assembly with conductive bridge
US20100016340A1 (en) * 2006-04-25 2010-01-21 Astex Therapeutics Limited Pharmaceutical compounds
JP5606734B2 (ja) 2006-04-25 2014-10-15 アステックス、セラピューティックス、リミテッド 医薬化合物
TW200801513A (en) 2006-06-29 2008-01-01 Fermiscan Australia Pty Ltd Improved process
UA99284C2 (ru) * 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ
AR074072A1 (es) * 2008-11-11 2010-12-22 Lilly Co Eli Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008075109A1 (en) * 2006-12-21 2008-06-26 Astex Therapeutics Limited Substituted piperidines having protein kinase inhibiting activity

Also Published As

Publication number Publication date
JP2013508382A (ja) 2013-03-07
CN102574852A (zh) 2012-07-11
KR101398268B1 (ko) 2014-05-23
KR20120068941A (ko) 2012-06-27
US20120149684A1 (en) 2012-06-14
CA2778291A1 (en) 2011-04-28
EP2491032A1 (en) 2012-08-29
ES2465094T3 (es) 2014-06-05
EP2491032B1 (en) 2014-04-16
JP5581390B2 (ja) 2014-08-27
BR112012011328A2 (pt) 2016-11-22
CA2778291C (en) 2014-02-11
MX2012004780A (es) 2012-08-23
EA020151B1 (ru) 2014-09-30
WO2011050016A1 (en) 2011-04-28
AU2010310786A1 (en) 2012-04-19
EA201270590A1 (ru) 2012-09-28
US8436002B2 (en) 2013-05-07
CN102574852B (zh) 2014-06-25

Similar Documents

Publication Publication Date Title
EP2491032B1 (en) Akt inhibitors
US20250122222A1 (en) Heterocyclic compounds and methods of use
JP7073359B2 (ja) ユビキチン特異的プロテアーゼ７の阻害剤としてのピペリジン誘導体
US20250179077A1 (en) Quinazoline compounds and uses thereof as inhibitors of mutant kras proteins
EP4281078A1 (en) Pharmaceutical combinations of sos1 inhibitors for treating and/or preventing cancer
KR101083177B1 (ko) 트리아졸로-피리다진 단백질 키나제 조정제
WO2023150394A1 (en) Methods for treatment of cancer
JP2025523624A (ja) がんの治療のための方法
US8148387B2 (en) AKT and P70 S6 kinase inhibitors
JP7723666B2 (ja) 環式化合物およびその使用方法
WO2020010197A1 (en) Fused pyrazine derivatives as a2a / a2b inhibitors
CN113164481A (zh) 环烷-1,3-二胺衍生物
CA2821777A1 (en) Substituted pyrimido[1,2-b]indazoles and their use as modulators of the pi3k/akt pathway
JP7808616B2 (ja) 環式化合物及びそれを使用する方法
JP2023541047A (ja) がんの治療のための複素環式ペリ縮環ｃｄｃ７キナーゼ阻害剤
CN117897159A (zh) 杂环化合物及使用方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired